News

The market size is estimated to reach USD 6.14 Billion by 2026, with the growth at a CAGR of 7.89% during the study period (2018-26)

Globally, more than 80+ companies are developing therapies based on different MoA, and Route of Administration

The market is expected to register a strong growth rate at a CAGR of 8.93% during the study period 2018-30

More than 80+ companies are developing novel therapies to transform the esophageal cancer treatment landscape

The market is anticipated to increase at a CAGR of 11.25% and will touch USD 33.37 billion by 2026

Several key companies, including Takeda, Zealand Pharma, VectivBio, and others, are developing novel products

The therapeutics pipeline is evolving with increased insight into biological pathways and mechanisms underlying epilepsy

The market size will expand at a CAGR of 6.18% (by 2026), owing to the advancement in devices and technologies

The upsurge in chronic diseases and the rising preference for medical devices will stimulate the market growth